ReviewCirculation research2013
Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair.
Review in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Decellularized cardiac ECM: A tissue-specific bioactive platform for drug release and cell delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- MuFaDDG: a sequence-based multiscale feature fusion framework for protein stability changes prediction.Bioinformatics (Oxford, England) · 2026Article
- Predicting protein stability changes upon mutations with dual-view ensemble learning from single sequence.Briefings in bioinformatics · 2025Article
- Injectable myocardium-derived hydrogels with SDF-1α releasing for cardiac repair.Biomaterials advances · 2025Article
- Customized Heparinized Alginate and Collagen Hydrogels for Tunable, Local Delivery of Angiogenic Proteins.ACS biomaterials science & engineering · 2025Article
- Stability Oracle: a structure-based graph-transformer framework for identifying stabilizing mutations.Nature communications · 2024Article
- Targeted Mutation of a Non-catalytic Gating Residue Increases the Rate ofJournal of agricultural and food chemistry · 2023Article
- Chitosan as Functional Biomaterial for Designing Delivery Systems in Cardiac Therapies.Gels (Basel, Switzerland) · 2021Review
- TMSB4 Overexpression Enhances the Potency of Marrow Mesenchymal Stromal Cells for Myocardial Repair.Frontiers in cell and developmental biology · 2021Article
- Crystal structure and receptor-interacting residues of MYDGF - a protein mediating ischemic tissue repair.Nature communications · 2019Article
- The bifunctional SDF-1-AnxA5 fusion protein protects cardiac function after myocardial infarction.Journal of cellular and molecular medicine · 2019Article
- Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide.International journal of cardiology · 2019Review
- A single injection of protein-loaded coacervate-gel significantly improves cardiac function post infarction.Biomaterials · 2017Article
- Cardiac repair in a mouse model of acute myocardial infarction with trophoblast stem cells.Scientific reports · 2017Article
- Intramyocardial Injection of Recombinant Adeno-Associated Viral Vector Coexpressing PR39/Adrenomedullin Enhances Angiogenesis and Reduces Apoptosis in a Rat Myocardial Infarction Model.Oxidative medicine and cellular longevity · 2017Article
- Innovative Therapeutics: Designer Natriuretic Peptides.JACC. Basic to translational science · 2016Article
- PEP-1-GSTpi protein enhanced hippocampal neuronal cell survival after oxidative damage.BMB reports · 2016Article
- Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.Biomaterials · 2016Review
- Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction.Nature medicine · 2015Article
- Advances in the treatment of aortic valve disease: is it time for companion diagnostics?Current opinion in pediatrics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A number of new and innovative approaches for repairing damaged myocardium are currently undergoing investigation, with several encouraging results. In addition to the progression of stem cell-based approaches and gene therapy/silencing methods, evidence continues to emerge that protein therapeutics may be used to directly promote cardiac repair and even regeneration. However, proteins are often limited in their therapeutic potential by short local half-lives and insufficient bioavailability and bioactivity, and many academic laboratories studying cardiovascular diseases are more comfortable with molecular and cellular biology than with protein biochemistry. Protein engineering has been used broadly to overcome weaknesses traditionally associated with protein therapeutics and has the potential to specifically enhance the efficacy of molecules for cardiac repair. However, protein engineering as a strategy has not yet been used in the development of cardiovascular therapeutics to the degree that it has been used in other fields. In this review, we discuss the role of engineered proteins in cardiovascular therapies to date. Further, we address the promise of applying emerging protein engineering technologies to cardiovascular medicine and the barriers that must be overcome to enable the ultimate success of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.